|
1
|
Chen SJ, Wang SC and Chen YC: The
immunotherapy for colorectal cancer, lung cancer and pancreatic
cancer. Int J Mol Sci. 22:128362021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fiorica F, Belluomini L, Giuliani J,
Urbini B, Milella M, Frassoldati A, Pilotto S and Giorgi C:
Abscopal effect and resistance reversion in nivolumab-treated
non-small-cell lung cancer undergoing palliative radiotherapy: A
case report. Immunotherapy. 13:971–976. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morad G, Helmink BA, Sharma P and Wargo
JA: Hallmarks of response, resistance, and toxicity to immune
checkpoint blockade. Cell. 185:5762022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dersh D, Holly J and Yewdell JW: A few
good peptides: MHC class I-based cancer immunosurveillance and
immunoevasion. Nat Rev Immunol. 21:116–128. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watson RA, Tong O, Cooper R, Taylor CA,
Sharma PK, de Los Aires AV, Mahé EA, Ruffieux H, Nassiri I,
Middleton MR and Fairfax BP: Immune checkpoint blockade sensitivity
and progression-free survival associates with baseline CD8(+) T
cell clone size and cytotoxicity. Sci Immunol. 6:eabj88252021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kouskou M, Thomson DM, Brett RR, Wheeler
L, Tate RJ, Pratt JA and Chamberlain LH: Disruption of the Zdhhc9
intellectual disability gene leads to behavioural abnormalities in
a mouse model. Exp Neurol. 308:35–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Masurel-Paulet A, KalscheuerV M, Lebrun N,
Hu H, Levy F, Thauvin-Robinet C, Darmency-Stamboul V, El Chehadeh
S, Thevenon J, Chancenotte S, et al: Expanding the clinical
phenotype of patients with a ZDHHC9 mutation. Am J Med Genet A.
64:789–795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hawkins E, Akarca D, Zhang M, Brkić D,
Woolrich M, Baker K and Astle D: Functional network dynamics in a
neurodevelopmental disorder of known genetic origin. Hum Brain
Mapp. 41:530–544. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shimell JJ, Shah BS, Cain SM, Thouta S,
Kuhlmann N, Tatarnikov I, Jovellar DB, Brigidi GS, Kass J,
Milnerwood AJ, et al: The X-linked intellectual disability gene
Zdhhc9 is essential for dendrite outgrowth and inhibitory synapse
formation. Cell Rep. 29:2422–2437. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schirwani S, Wakeling E, Smith K, Study
DDD and Balasubramanian M: Expanding the molecular basis and
phenotypic spectrum of ZDHHC9-associated X-linked intellectual
disability. Am J Med Genet A. 176:1238–1244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu P, Jiao B, Zhang R, Zhao H, Zhang C,
Wu M, Li D, Zhao X, Qiu Q, Li J and Ren R: Palmitoylacyltransferase
Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic
Nras. Leukemia. 30:1225–1228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Ma H, Wang Z, Zhang S, Yang H and
Fang Z: EZH2 palmitoylation mediated by ZDHHC5 in p53-mutant glioma
drives malignant development and progression. Cancer Res.
77:4998–5010. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Noland CL, Gierke S, Schnier PD, Murray J,
Sandoval WN, Sagolla M, Dey A, Hannoush RN, Fairbrother WJ and
Cunningham CN: Palmitoylation of TEAD transcription factors is
required for their stability and function in hippo pathway
signaling. Structure. 24:179–186. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu
JL, Wei Y, Xia W, Hou J, Qiu Y and Hung MC: Palmitoylation
stabilizes PD-L1 to promote breast tumor growth. Cell Res.
29:83–86. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mansilla F, Birkenkamp-Demtroder K,
Kruhøffer M, Sørensen FB, Andersen CL, Laiho P, Aaltonen LA,
Verspaget HW and Orntoft TF: Differential expression of DHHC9 in
microsatellite stable and instable human colorectal cancer
subgroups. Br J Cancer. 96:1896–1903. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma P and Allison JP: Dissecting the
mechanisms of immune checkpoint therapy. Nat Rev Immunol. 20:75–76.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cerezo M, Guemiri R, Druillennec S,
Girault I, Malka-Mahieu H, Shen S, Allard D, Martineau S, Welsch C,
Agoussi S, et al: Translational control of tumor immune escape via
the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 24:1877–1886.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong
T, Chen H and Wang C: Immunotherapy: Reshape the tumor immune
microenvironment. Front Immunol. 13:8441422022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yenyuwadee S, Aliazis K, Wang Q,
Christofides A, Shah R, Patsoukis N and Boussiotis VA: Immune
cellular components and signaling pathways in the tumor
microenvironment. Semin Cancer Biol. 86:187–201. 2022. View Article : Google Scholar : PubMed/NCBI
|
